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In the last decades a large amount of evidence linked rheumatoid arthritis (RA) to atherosclerosis. In fact, RA patients have an
increased risk of cardiovascular events that is not fully explained by other classic cardiovascular risk factors. RA and atherosclerosis
may share several common pathomechanisms and inflammation undoubtedly plays a primary role. The proinflammatory
cytokines such as tumor necrosis factor alpha and interleukin-6, involved in the pathogenesis of RA, are also independently
predictive of subsequent cardiovascular disease (CVD). In RA, inflammation alters HDL constituents and the concentration of LDL
and HDL, thus facilitating atherosclerosis and CVD events. On the other hand, also the increase of oxidative processes, frequently
observed in RA, induces atherosclerosis. Interestingly, some genetic polymorphisms associated with RA occurrence enhance
atherosclerosis, however, other polymorphisms associated with RA susceptibility do not increase CVD risk. Several other
mechanisms may influence atherosclerotic processes in RA. Moreover, atherosclerosis may be directly mediated also by underlying
autoimmune processes, and indirectly by the occurrence of metabolic syndrome and impaired physical activity. Finally, the eﬀects
of RA therapies on cardiovascular system in general and on atherosclerosis in particular are really wide and diﬀerent. However, the
starting point of every RA treatment is that disease control, or better remission, is the best way we have for the reduction of CVD
occurrence.
1. Introduction
Rheumatoid arthritis (RA) and atherosclerosis are two
inflammatory diseases strictly linked; in fact, although joint
involvement is the prototypical feature of RA, atherosclerotic
cardiovascular diseases (CVDs) are the major cause of
mortality and morbidity in these patients [1, 2]. Therefore,
the increased CVD risk occurs even early during the course of
RA, being so intended as a possible preclinical manifestation
of the disease [3]. On this basis, the understanding of com-
monly shared pathomechanisms is mandatory for the right
treatment of RA, in order to reduce atherosclerosis and the
subsequent impact of CVD, on these patients. Moreover, it’s
also important to evaluate the diﬀerent eﬀects of RA
therapies (i.e., corticosteroids, NSAIDs, DMARDs, anti-TNF
agents, and other biological drugs) on cardiovascular risk. All
these aspects will be analyzed in this paper.
2. The Link between Atherosclerosis
and Rheumatoid Arthritis
In the last years, a large amount of data improved the
understanding of pathomechanisms leading to atherosclero-
sis appearance, thus allowing its classification among inflam-
matory disorders [4], similarly to RA. But this is not the only
point that links atherosclerosis and RA; undoubtedly, smoke
is the most evident one, being clearly involved in the appear-
ance of both diseases [5, 6]. Moreover, it is well established
that RA patients had an increased risk of cardiovascular
events that is not fully explained by smoke and other classic
CVD risk factors [3]. Therefore, atherosclerotic processes are
increased in RA [7, 8], and subsequently also CVD risk.
Inflammation plays a primary role in this relationship; in
fact, in patients with recent onset polyarthritis, baseline CRP
levels were independent predictors of CVD-related death,
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with an hazard ratio of 3.3, and this after adjusting for age,
sex, smoking status, rheumatoid factor positivity, swollen
joint counts, and Health Assessment Questionnaire score
[9]. Furthermore, it is interesting to observe that the risk of
CVD events, myocardial infarction in particular, is increased
also in the 2 years preceding formal diagnosis of RA [10];
so, on this basis, it is possible to speculate that systemic
inflammation may increase atherosclerosis before it aﬀects
the joints [11]. On the other hand, the longer the duration
of disease, the higher the risk of plaques in the carotid artery
[12] and CVD events [13], thus indicating that chronic RA-
related inflammation increases the CVD risk and suggesting
the need of early therapeutic intervention in these patients.
Therefore, between the proinflammatory cytokines involved
in the pathogenesis of RA, tumor necrosis factor (TNF) alpha
and interleukin (IL)-6 are independently predictive of subse-
quent CVD events in these patients. In fact, these cytokines
are released into the systemic circulation, with a large
amount of systemic eﬀects, in particular on endothelium
[11]. The result is a cascade of alterations throughout our
organism that leads to the proatherogenic profile that is
prototypical of RA.
3. Pathomechanisms Involved in Rheumatoid
Atherosclerosis Appearance
RA-related inflammation may lead to atherosclerosis occur-
rence in several ways. The enhancement of oxidative modifi-
cation of LDL, that has been linked to TNF-α action through
the stimulation of superoxide secretion from monocytes
and endothelial cells, is among involved processes [11];
moreover, also HDL constituents may be altered by the
inflammation, thus losing their ability to remove cholesterol
from atherosclerotic lesions and reducing their antioxidant
activity [14]. On the other hand, not only the function
but also the concentration of LDL and HDL is altered in
RA; in particular small-dense LDLs are increased, whereas
small-dense HDLs are decreased [11], thus leading to an
unbalance toward atherosclerosis appearance. Therefore,
HDL impairment may be related to paraoxonase (PON)
activity reduction, that has been found in RA, in particular
in patients with both active [15] and quiescent disease [16];
in fact, PON is a peculiar enzyme linked to HDL that binds
and destroys oxidized lipids, thus reducing atherosclerosis
occurrence [11]. Another aspect is the increase of oxidative
processes, that in RA is demonstrated in several ways, for
example, by the depletion of vitamins A and E and by the
reduced degradation of asymmetric dimethyl-L-arginine
(ADMA), an endogenous inhibitor of nitric oxide synthase
(NOS) [11, 17]. Recently, the attention has been pointed out
on Interleukin-17; this cytokine, involved in RA pathogen-
esis [18], may accelerate myocardial fibrosis and promote
atherosclerosis in non-RA animal models [19]. Therefore,
elevated circulating IL-17 levels have been detected in
patients with acute coronary syndromes [20]. In RA patients,
this cytokine influences microvascular function and arterial
compliance, thus playing a significant role in development of
endothelial dysfunction and CVD in the setting [21].
But although these factors are important, the “sine qua
non” condition for atherosclerosis appearance is the occur-
rence of endothelial dysfunction, a feature frequently des-
cribed in RA patients [22]; this generic term indicates the
endothelial phenotypic alterations that appear in response to
a large amount of noxious stimuli. The increased expression
of adhesion molecules such as ICAM-1, VCAM-1 and
E-selectin, the enhancement of pro-inflammatory cytokines
(TNF-α, IL-1, IL-6, IFN-γ), and the upregulation of oxidative
stress processes are the starting point of this condition
[23]; moreover, also the increase of leptin and resistin
(proatherogenic hormones) and the decrease of adiponectin
(antiatherogenic hormones) may alter endothelial home-
ostasis in RA patients [22]. These features lead to an increase
in endothelial permeability to lipoproteins and plasma con-
stituents, with subsequent infiltration of lipids into the
arterial wall and migration of monocytes and T-lymphocytes
into the vessel intima [24]. Foam cells and fatty streaks
appearance within the vessel wall is the consequence of
these processes [25]. The inflammatory state leads to smooth
muscle cells proliferation, that migrates into the lesion with
subsequent vessel walls thickening and fibrotic tissue deposi-
tion. The result is the appearance of atherosclerotic plaques,
that appear as a dynamic lesions, due to the large amount
of ongoing modifying processes; but these lesions are also
unstable, with an increased risk of rupture [24]. Therefore,
recent data showed that endothelial progenitor cells (EPCs)
action is altered in RA [26]; EPCs are mononuclear cells
present in blood, bone marrow, and vessels that express spe-
cific endothelial markers and can help the repair of injured
endothelium [11]. So, on this basis it is possible to speculate
that in RA not only atherosclerosis formation mechanisms
are increased, but also reparatory mechanisms are impaired.
4. Genetic and Autoimmunity: Beside Classic
Inflammation Pathways
After the identification through genome-wide association
studies of a large amount of putative loci that may increase
the risk of CVD in the general population, several researches
have been addressed to the identification of a genetic back-
grounds also for RA-related atherosclerosis. In particular,
recent data evidenced that rs599839 A/G polymorphism
(chromosome 1p13.3), previously associated with higher
plasma total and LDL cholesterol levels and with an increased
risk of CVD in general population, seems to increase the
risk of endothelial dysfunction also in RA patients without
evidence of overt CVD [27]. Another identified polymor-
phism,MIA3 rs17465637 A/C, enhances the risk of CVD also
in RA, although only in case of concomitant dyslipidemia
[28]; MIA3 protein is involved in leukocyte adhesive inter-
actions with vascular endothelium, reduces attachment, and
promotes migration of monocytes across the endothelium,
thus leading to foam cells and fatty streak appearance with
vessel walls [29]. Likewise to general population, acid phos-
phatase locus 1∗C allele is associated with CVD events in
RA population; as the authors state, this may result from the
major production of the S isoform of low molecular weight
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phosphotyrosine phosphatase by this allele, whichmay influ-
ence the regulation of energy metabolism and the response
to oxidative stress [30]. Therefore, a potential influence on
CVD risk in RA patients has been suggested also for the
CCR5Δ32 deletion [31], MTHFR 1298 A > C [32] and IL6-
174 [33] gene polymorphisms.
Due to the relevance of TNFα in the inflammatory path-
way of RA, several polymorphisms of this cytokine have been
evaluated as a potential risk factors for atherosclerosis occur-
rence in this setting. In fact, both TNFα rs1800629 [34] and
TNFα 1031 T/C [35] polymorphisms were associated with
an enhancement of atherogenic processes in RA patients.
Moreover, among the several HLA-DRB1 alleles involved in
RA susceptibility, HLA-DRB1∗0404 [36] is associated with
an increased risk of endothelial dysfunction and CVD events
in RA patients. In particular, patients with HLA-DRB1∗0404
alleles had decreased endothelium-dependent vasodilata-
tion with respect to other RA patients; interestingly, in these
patients the authors do not find correlations between dis-
ease-related parameters (i.e., disease duration, activity
parameters) and endothelial dysfunction. Moreover, the
authors excluded also the occurrence of linkage disequilib-
rium with TNF microsatellite alleles, thus confirming that
cardiovascular risk in RA may be partially genetically deter-
mined by HLA-DRB1∗0404 alleles. However, up to now, the
biological mechanisms underlying this association are not
established, although antigen presentation and upregulated
expression of HLA-DRβ1 molecules on the endothelial cell
wall may be involved [37].
It is interesting to observe that some polymorphisms
may enhance CVD risk in RA patients carrying the HLA-
DRB1∗0404 allele, as recently demonstrated for endothelial
nitric oxide synthase (NOS2A and NOS3) gene polymor-
phisms [38]. Another gene involved in RA susceptibility, the
methionine sulfoxide reductase A (MSRA) gene, in particular
the minor allele G, is associated with an increased risk of
ischaemic heart disease in anticyclic citrullinated peptide
antibodies (ACPAs) positive RA [39]. These data confirm
that similarly to general healthy population, also in RA the
genetic background influences atherosclerosis occurrence.
However, some gene polymorphisms are associated with RA
susceptibility but not with an increased CVD risk, as,
for example, PTPN22, STAT4 and TRAF1/C5 [40], IL6R
rs2228145 and IL6ST/gp130 rs2228044 [41], VEGFA
rs2010963 and the rs1570360 [42], and MHCIITA rs3087456
and rs4774 [43]; on the other hand, potentially involved
polymorphisms, such as those of macrophage migration
inhibitory factor-173, do not link with RA susceptibility and
atherosclerosis occurrence [44]. These results by itself are
very intriguing, because they indicate that the pathway of
atherosclerosis in RA is really complex, being influenced by
several factors, that may transcend inflammation and genetic
background. In fact, atherosclerosis in RA may be mediated
also by underlying autoimmune processes; in particular,
antibodies against oxidized low-density lipoprotein have
been found to be associated with subclinical atherosclerosis
in recent-onset RA [45–47]. Moreover, anti-apoA-1 IgG are
increased in RA patients, being also significant predictors of
CVD in these patients [48]. The APCAs, that are important
serological markers of RA, have been assessed as a possible
markers of atherosclerosis appearance in this setting. In
particular, Gerli et al. [49] showed that RA patients with
detectable circulating APCA had higher intima-media
thickness (IMT) at internal carotid arterial wall than patients
without evidence of these antibodies, thus linking ACPA
positivity and subclinical atherosclerosis in RA. Recently,
the attention has been pointed out on another citrullinated
antibody, the antimodified citrullinated vimentin (anti-
MCV); changes in serum levels of this antibody correlate
with changes in atherogenic ratios (total cholesterol/HDL-C
and LDL-C/HDL-C), apolipoprotein A-I, and carotid IMT,
thus becoming a possible marker of subclinical atheroscle-
rosis in RA [50]. But the autoantibodies may be sometimes
protective, as demonstrated for antibodies against phos-
phorylcholine (anti-PC) [51], that probably play a role in the
clearance of atherosclerotic plaques [52]. In fact, low IgM
anti-PC levels are associated with an increased occurrence of
carotid plaques in RA patients [53].
So, taken together, these data indicate that between RA
and atherosclerosis there is a very close link, that is not
limited to inflammation processes and involves also genetic
and autoimmunity; in fact, this link is so deep that some
authors include atherosclerosis among the extra-articular
manifestations of RA [11].
5. Other Factors Involved in
Atherosclerosis Appearance
In order to better understand the increased CVD risk in
RA we should take into account also other indirect factors.
In fact, metabolic syndrome is common in both early and
long-standing RA, as indicated by the increase of waist
circumference and blood pressure, by the occurrence of dys-
lipidaemia and abnormal visceral fat distribution [54, 55].
Therefore, also the impaired physical activity may aﬀect the
risk of CVD in these patients; in fact, low physical activity
in RA women is associated with increased levels of oxidized
low-density lipoprotein (oxLDL) and insulin, with reduced
levels of HDL, Apo A1 and atheroprotective natural anti-PC,
and, in particular, with insulin resistance [56]. This latter
in particular is associated with impaired vascular insulin
signaling and blunted vascular eﬀects of insulin, that lead
to atherogenesis appearance, although through mechanisms
that are not completely established [57].
6. Atherosclerosis and RA Therapies
The eﬀects of RA therapies on cardiovascular system in
general and on atherosclerosis in particular are really wide
and diﬀerent. In fact, RA treatment comprehends drugs that
may either increase or reduce CVD risk [58]. However, the
starting point of every RA treatment is that disease control,
or better remission, is the best way we have for the reduction
of cardiovascular morbidity and mortality in these patients
[59]; but RA patients always ask for pain control, so that we
should take into account the drugs used for pain control.
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6.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
NSAIDs are largely used in RA as a painkillers; actually two
main classes of NSAIDs are available: COXIBs, that act
selectively on inducible COX-2, and classic NSAIDs, that
block both COX-1 and COX-2. These classes of drugs have
been recently linked to an increased CVD risk, first for
rofecoxib [60], with subsequent reduced trend in COXIBs
prescription [61], and then also for other COXIBs and
NDSAIDs [62]. However, the relationship between COXIBs/
NSAIDs and atherosclerosis occurrence is not clearly estab-
lished; in particular, some authors hypothesized that COXIBs
may promote the early appearance of atherosclerosis,
whereas in case of more advanced stages, they may demon-
strate protective/antiatherogenic properties [63]; it is inter-
esting to observe that this dualism has been confirmed
also in subsequent studies for both COXIBs and NSAIDs
[64–67].
6.2. Corticosteroids. Corticosteroids (CTs) are powerful anti-
inflammatory agents widely used in the treatment of RA
[68]. Although long-term CTs use may be associated with a
dose-related increased risk of CVD, due to eﬀects on blood
pressure, insulin resistance, lipid profile, body weight, and
fat distribution [69–71], up to now there is no evidence
that low-dose CTs may influence atherosclerosis appear-
ance in RA [72]. Moreover, other data showed that anti-
inflammatory and antiproliferative actions on vessel walls
of low-term CTS therapy may reduce first atherosclerosis
occurrence and then CVD risk [58].
6.3. DiseaseModifying Antirheumatic Drugs (DMARDs). The
term DMARDs indicates a wide group of drugs poten-
tially able to inhibit the occurrence/progression of articular
damage in RA patients [73]. Therefore, DMARDs may
reduce also CVD risk by influencing atherosclerotic processes
directly through inflammation; but in order to obtain this
goal, the early identification and treatment of patients with
RA are crucial [74]. Among DMARDs are listed drugs such
as methotrexate (MTX), leflunomide (LFN), sulphasalazine
(SSZ), cyclosporine (CsA), and hydroxychloroquine (HCQ).
MTX is today the anchor DMARDs for RA treatment;
moreover, recent studies showed that although increasing
serum homocysteine levels [75], MTX reduces CVD-related
mortality and morbidity in RA with respect to other
DMARDs [58, 76, 77]; this suggests that reducing RA
inflammation, MTX may also reduce collateral damage such
as atherosclerosis. Therefore, MTX-related atherogenesis
reduction has been confirmed also in a recent experimental
model [78]. Data on other DMARDs are scanty; LFN may
improve vascular function through the inhibition of NFκB
signal transduction pathway in endothelial cells, the reduc-
tion of subendothelial migration of peripheral blood mono-
nuclear cells, and, finally, to the impairment of antigen
presenting dendritic cells [58]. However, despite these poten-
tial beneficial eﬀects on atherogenesis, LFN-related arterial
hypertension may increase CVD risk [79]. On the other
hand, despite the established anti-inflammatory eﬀects, also
CsA has been associated with an increased susceptibility
to atherosclerosis and development of hyperlipidemia; in
fact, CsA demonstrates complex eﬀects on lipoprotein
metabolism and bile acid production and aﬀects endothelial
cells, smooth muscle cells, and macrophages, all critical for
atherosclerotic process occurrence [80]. The eﬀects of SLZ
on atherosclerosis have been recently evaluated, although in
patients with coronary artery disease without RA; the final
findings of the study suggested that SLZ is not the opti-
mal anti-inflammatory treatment for reversing endothelial
dysfunction in cardiovascular disease [81]. Finally, hydrox-
ychloroquine exerts an antithrombotic eﬀect and improves
glucose and lipid profiles in treated patients, being a poten-
tially protective factor against atherosclerosis appearance
[58].
6.4. Biological Agents
6.4.1. Anti-TNF Agents (Infliximab, Etanercept, Adalimumab,
Golimumab, and Certolizumab). These drugs act through the
inhibition of TNF alpha, a proinflammatory cytokine playing
a primary role in RA appearance [82]; however, as previously
described, TNF alpha has been implicated also in the patho-
genesis of RA-related atherosclerosis. According to these sug-
gestions, in the last decade numerous publications suggested
that TNF blockers exert significant eﬀects on the vasculature
[83, 84] and decrease the incidence of CVD in RA patients
[85]. The cardioprotective eﬀect of TNF inhibition in RA
may be related to several factors, as, for example, the increase
of HDL levels; therefore, these drugs do not aﬀect LDL
levels or atherosclerotic index (i.e., TC/HDL ratio) [86]. On
the other hand, these drugs may reduce significantly insulin
levels and the insulin/glucose index, as well as improve
insulin resistance [58, 87] and also a dramatic reduction of
resistin, an adipokine that showed strong correlation with C-
reactive protein, was observed following infliximab infusion
in RA patients undergoing this therapy because of severe
disease [88]. Likewise, improvement of endothelial function
following anti-TNF-alpha administration has been observed
in RA patients with severe disease refractory to conventional
DMARDs therapy [89, 90].
It is also important to remember that levels of circulating
adhesion molecules, such as serum E-selectin and inter-
cellular adhesion molecule-1, are decreased following these
treatments [58]. However, despite this behavior, the use of
TNF-blockers in patients with severe chronic heart failure
may have detrimental eﬀects on cardiac function, and this
despite the increase of circulating levels of TNF observed;
consequently, severe heart failure contraindicates anti-TNF
treatment in patients with RA [91].
6.4.2. Other Biological Drugs (Tocilizumab, Abatacept, and
Rituximab). Today a large number of non-anti-TNF bio-
logical drugs are available for RA treatment. The targets of
these drugs are very wide; tocilizumab (TCZ) acts through
the inhibition of IL-6, another proinflammatory cytokine
that may contribute to atherosclerosis processes; in fact, TCZ
improves endothelial function and aortic stiﬀness in RA and
this despite the increase of total and LDL-cholesterol [58].
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Abatacept is a fully human soluble fusion protein consisting
of the extracellular domain of human CTLA-4 and the mod-
ified Fc portion of human IgG1; to date, there is no data on
the eﬀects of this drug on atherosclerosis. Rituximab (RTX)
is a chimeric monoclonal antibody against CD20 depleting
B cells in peripheral blood; also RTX data are scanty,
although, at least in short term, this drug seems to improve
endothelial dysfunction, carotid atherosclerosis, and lipid
profile in RA [92, 93].
7. Conclusions
Rheumatoid arthritis and atherosclerosis are strictly linked
in several ways; this link is so strong that atherosclerosis
may be considered an “extra-articular manifestation” of the
disease, leading to an increased risk of CVD [11]. Moreover,
the impact of this “extra-articular manifestation” on patients
survival is of primary importance, being in fact CVD, the
main prognostic factor in this setting [1]. So it is important
to screen and monitor RA patients for the occurrence of
existing traditional-risk factors for CVD appearance, in order
to reduce the impact on cardiovascular system, as suggested
in the recently published EULAR evidence-based recom-
mendations for cardiovascular risk management in patients
with RA [94]. Therefore, according to literature evidence,
it will be of primary importance that all risk stratifications
models used to calculate CVD risk in general populations
consider also RA among risk factors [95]. Additional tools
such as the use of carotid ultrasonography in patients with
RA that exhibit an intermediate risk have recently been sug-
gested [96]. However, further studies are needed to better
establish the cardiovascular risk of patients with RA. Regard-
ing the treatment of atherosclerosis in RA patients, beside
the classical approach [97], RA control, or better remission,
should be considered the reference therapeutic strategy for
the reduction of CVD risk in this setting [94].
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